UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrioli, R, Sabatino, M, Fiaschi, A I, Marsili, S, Pozzessere, D, Messinese, S, Correale, P, Civitelli, S, Tanzini, G, Tani, F, De Martino, A, Marzocca, G, Lorenzi, M, Giorgi, G, Francini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409570/
https://www.ncbi.nlm.nih.gov/pubmed/14735168
http://dx.doi.org/10.1038/sj.bjc.6601521
Descripción
Sumario:A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.

Ejemplares similares